AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03705494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based peer counselling (web-based) intervention
Description: The intervention consists of 5-6 home based visits (web-based) over 6 months by trained peer counsellors who will focus on breastfeeding among mothers who have already decided to breastfeed and are interested in this programme.
Study NCT01812304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hands-on training
Description: the intervention consists of a predefined hands-on training program including 25 technical steps to manage a vaginal breech
Study NCT01812304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: frontal teaching
Description: one teacher demonstrates all 25 items listed in the OSATS checklist. Probands listen and watch.
Study NCT02911987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity training (HIT) program
Description: The participants are randomly divided through use of sealed envelopes into four groups that all follow high intensity training (HIT) programs. Each training group follows of a 12 week program (2x/week, 2h). All training will be conducted under the guidance of expert therapists.
Study NCT02911987 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: moderate intensity training (MIT) exercise therapy
Description: MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group).
Study NCT02486068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABSORB scaffold
Study NCT02486068 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience
Study NCT00021866 — intervention group
Intervention type: BEHAVIORAL
Intervention: Differential Abilities Scale
Description: IQ measurement at 3, 4.5 and 6 years of age
Study NCT00021866 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychological Testing
Description: Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age
Study NCT00881829 — intervention group
Intervention type: DEVICE
Intervention: Pulse Oximeter, Blood Pressure, Respiratory Rate, Respiratory Gasses, Temperature
Description: Measurement of physiological parameters.
Study NCT02085577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml
Description: Ketamine (25 mg/ml) bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/hour that is terminated when the last suture to the skin has been performed.
Study NCT02085577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic sodium chloride 0.9 percent
Description: Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/hour that is terminated when the last suture to the skin has been performed.
Study NCT02085577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g
Description: Paracetamol 1 g orally 1 hour preoperatively and every 6 hours after extubation time during the first 24 hours.
Study NCT02085577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol 1 g
Description: Paracetamol 1 g orally 1 hour preoperatively and every 6 hours after extubation time during the first 24 hours.
Study NCT02085577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulphate 1 mg/ml
Description: Morphine Sulphate 1 mg/ml administered as patient-controlled analgesia (PCA, bolus 2.5 mg, lockout 5 minutes) 0-24 hours postoperatively
Study NCT02085577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine Sulphate 1 mg/ml
Description: Morphine Sulphate 1 mg/ml administered as patient-controlled analgesia (PCA, bolus 2.5 mg, lockout 5 minutes) 0-24 hours postoperatively
Study NCT02085577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulphate 1 mg/ml
Description: Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.
Study NCT02085577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine Sulphate 1 mg/ml
Description: Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.
Study NCT02085577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 2 mg/ml
Description: Ondansetron 2 mg/ml 4 mg iv in case of moderate to severe nausea, supplemented by Ondansetron 1 mg iv if needed
Study NCT02085577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron 2 mg/ml
Description: Ondansetron 2 mg/ml 4 mg iv in case of moderate to severe nausea, supplemented by Ondansetron 1 mg iv if needed
Study NCT02085577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual daily opioids
Description: The patients usual daily opioid consumption are administered during the study period
Study NCT02085577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Usual daily opioids
Description: The patients usual daily opioid consumption are administered during the study period
Study NCT01052142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipovaxin-MM
Description: Patients will receive three doses of Lipovaxin-MM by intravenous infusion at intervals of four weeks OR patients will receive 4 doses of Lipovaxin-MM by intravenous infusion at weekly intervals
Study NCT02085577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulphate 1 mg/ml
Description: Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 minutes before expected awakening.
Study NCT02085577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine Sulphate 1 mg/ml
Description: Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 minutes before expected awakening.
Study NCT01210911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine
Study NCT01210911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gemcitabine
Description: Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine
Study NCT01210911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food
Study NCT01210911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: erlotinib
Description: Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food
Study NCT01210911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
Study NCT01210911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
Study NCT01935505 — intervention group
Intervention type: BEHAVIORAL
Intervention: Consulting
Description: The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
Study NCT01935505 — intervention group
Intervention type: DRUG
Intervention: Nicotine patch
Description: According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
Study NCT01935505 — intervention group
Intervention type: BEHAVIORAL
Intervention: Telephone intervention
Description: Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
Study NCT01935505 — intervention group
Intervention type: BEHAVIORAL
Intervention: Consulting+Telephone+Drug intervention
Description: Include all the above interventions
Study NCT04721847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: In first part educational content will be designed to be given in group of patients in six sessions by PNE booklet. The six sessions are 1.5 hours long (9 hours) and will be given at a frequency of 1 session per week. Final session will be given to solve doubts, and to provide additional information to the educational program. Book for additional material will be delivered to participants.
Study NCT02085577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil 5 microgram/ml
Description: Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.
Study NCT02085577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil 5 microgram/ml
Description: Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.
Study NCT02414295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell injection
Description: Aspirated bone marrow then separation for Mesenchymal stem cell
Study NCT00632593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Gastric Bypass
Study NCT01520662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of a secure web-based patient Wellness Portal
Description: Patients in intervention practices will review and update their wellness records, risk factor information, allergy and contraindication profile, and personal preferences through the Wellness Portal before they visit their primary care provider.
Study NCT04560114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils
Description: The patient will be invited to inhale the essential oils via the stick:~* 4 times a day before each meal and snack.~* if necessary when nausea appears, as many times as he deems necessary.
Study NCT03949231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1/PDL1 inhibitor
Description: Infusion of PD1/PDL1 inhibitor through peripheral vein or hepatic artery.
Study NCT02446366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02446366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03426488 — intervention group
Intervention type: BEHAVIORAL
Intervention: VIP - Västerbotten Intervention Programme
Description: Intervention on CVD (cardiovascular disease) and diabetes
Study NCT04721847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical therapy
Description: Control group will be treated by Conventional Physical therapy like TENS, stretching and strengthening exercises. Intervention will be initiated with warm up period (joint mobility exercises) for the duration of 5 mins and ended up with cool down period (relaxing exercises i.e. deep breathing) for the duration of 5 mins.
Study NCT02446366 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo hypofractionated SBRT
Study NCT02454582 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Somanetics INVOS Cerebral Oxymeter 5100C
Description: Non- invasive transcranial near infrared cerebral oxygenation with or without CPAP
Study NCT02056288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
Study NCT03715257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 14F staged extubation set guidewire
Description: 14F staged extubation set guidewire is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts.~Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2\<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)
Study NCT02056288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction. Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml).
Study NCT00532857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/Gemcitabine/Trastuzumab
Description: 80 mg/m2 of paclitaxel 1,200 mg/m2 of gemcitabine, day 1, day 8 every 3-week. trastuzumab at a dose of 4 mg/kg IV on D1 of first treatment cycle subsequently given weekly at a dose of 2 mg/kg
Study NCT03715257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tube changing catheter
Description: Tube changing catheter Tube changing catheter is an alternative extubation device. Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2\<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)
Study NCT03322137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SNA-120
Description: Pegcantratinib ointment
Study NCT00965094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: One tablet containing 0.25, 0.5mg or 0.75 mg. Initially 2 mg/day. Afterwards based on blood level (target 6-10 ng/mL)
Study NCT00965094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (FK506)
Description: Capsules 0.5 mg, 1 mg. Dosing according to blood level.
Study NCT00965094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: One vial containing 20 mg lyophilisate. 2 x 20 mg \[day 0 (2 hrs prior to Tx) and day 4 post Tx\] to be applied as 10 sec. bolus injection, i.v.
Study NCT00965094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: One vial containing 20 mg lyophilisate. 2 x 20 mg \[day 0 (2 hrs prior to Tx) and day 4 post Tx\] to be applied as 10 sec. bolus injection, i.v.
Study NCT00965094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric Coated Mycophenolate Sodium (EC-MPS)
Description: One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)
Study NCT00965094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric Coated Mycophenolate Sodium (EC-MPS)
Description: One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)
Study NCT00965094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Used according to Israeli standards. A minimum dose of 5mg \[prednisone, or equivalent, was used throughout the study period.
Study NCT00965094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Used according to Israeli standards. A minimum dose of 5mg \[prednisone, or equivalent, was used throughout the study period.
Study NCT03996460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fifteen (15) patients in group 1 will receive the sachet of matching placebo ( equivalent to a capsule of placebosugar pill) orally daily for 12 weeks (90 days) without food.
Study NCT03996460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 192 mg powder of K0706
Description: Fifteen (15) patients in group 2 will receive the sachet of 192 mg powder of K0706 ( equivalent to 96 mg capsule of K0706) orally for 12 weeks (90 days) without food.
Study NCT03996460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 384 mg powder of K0706
Description: Fifteen (15) patients in group 3 will receive the 384 mg powder of K0706 (equivalent to 192 capsule of K0706) orally daily for 12 weeks (90 days) without food.
Study NCT04228315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: radical cure dosing
Study NCT03322137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo ointment to mimic Pegcantratinib ointment
Study NCT04228315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: radical cure dosing
Study NCT04258098 — intervention group
Intervention type: DRUG
Intervention: Oral antibiotics ( Streptomycin ,metronidazole )
Description: Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. Streptomycin 1g plus metronidazole 0.2g was prescribed 3 times a day for 3 days before surgery in the OA+MBP group patients.
Study NCT05560321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sani24
Description: Disinfectant
Study NCT05560321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Disinfection
Description: Routine disinfection at the study hospital
Study NCT03478124 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive evaluation
Description: An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.
Study NCT01703312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: Drug administered by subcutaneous injection
Study NCT05560321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Disinfection
Description: Routine disinfection at the study hospital
Study NCT01492803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Probiotic is a live microorganism that when administered in adequate amounts confer a health benefit on the host. It is classified by the FDA as generally recognized as safe (GRAS)
Study NCT01703312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omalizumab
Description: Drug administered by subcutaneous injection
Study NCT01492803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo sticks will contain approximately 1 g maltodextrin
Study NCT03446573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG + 3TC
Description: DTG+3TC is supplied as white, oval, film-coated, fixed dose combination tablet. The tablets will be available in packed high density polyethylene (HDPE) bottles with induction seals and child-resistant closures.
Study NCT03446573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAF based regimen (TBR)
Description: Participants will continue to receive their TBR.
Study NCT04641039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior lumbar disc annulus removal versus replacement
Description: Owestry scale, SF12, Facet joint arthritis measured with Pathria scale, discal degeneration measured with Modic and Phirrmann scales
Study NCT04031768 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Timing of rest prior to blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which they rest prior to each set of measurements.
Study NCT04900857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needle
Description: Local twitch responses (LTRs) were obtained by multiple rapid insertions of the needle in and out of the point, similar to Hong's rapid-entry and rapid exit technique. Hong 1994). The needle was not removed from that site for the maximum stimulation time of 1 minute to 3 minutes after a local twitch response was obtained.
Study NCT04900857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Localize vibration
Description: the vibration was applied with 110 Hz and 5.57 mm amplitude.
Study NCT04275635 — intervention group
Intervention type: DEVICE
Intervention: Orthokeratology lenses
Description: Orthokeratology lenses
Study NCT03286075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS Anode session
Description: The aim of this unique anode tDCS session is to study the possibility of enhancing emotional processing, attentional resources and physiological responses in healthy subjects.~The arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system).